Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir for Congenital CMV-related Deafness
NCT02606266Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valganciclovir in congenital cytomegalovirus infection (cCMV), sponsored by Assistance publique - Hôpitaux de Paris. Started Jul 2017; status: terminated.
02
Drugs
valganciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on NCT02606266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02606266.